Background {#Sec1}
==========

Functional mitral regurgitation, a consequence of left ventricular (LV) remodeling despite normal mitral valve structure, is one of the common and severe complications in non-ischemic dilated cardiomyopathy patients (DCM) \[[@CR1]--[@CR4]\]. It has been reported that the annular enlargement and mitral leaflet tethering by the displacement of papillary muscles due to LV dilatation are the main mechanisms of functional mitral regurgitation \[[@CR5]\]. To date, little is known regarding the relationship between papillary muscle function and mitral regurgitant fraction in DCM patients.

Native (non-contrast) T~1~ mapping has emerged as a cardiovascular magnetic resonance (CMR) method to assess LV diffuse myocardial fibrosis \[[@CR6]\]. Studies have shown that native T~1~ mapping detects diffuse myocardial abnormalities in hypertrophic cardiomyopathy and DCM \[[@CR7]--[@CR9]\]. The extent of myocardial damage by acute myocardial infarction can also be accurately assessed by native T~1~ mapping \[[@CR10]\]. Diffuse myocardial abnormalities in patients with cardiac amyloidosis \[[@CR11]\] and Anderson-Fabry disease \[[@CR12], [@CR13]\] can be assessed by native T~1~ mapping. However, data is lacking regarding native T~1~ mapping of papillary muscles in these myopathies, including DCM.

Therefore, we sought to examine papillary muscle native T~1~ mapping in DCM and to investigate the relationship between papillary muscle native T~1~ time and functional mitral regurgitation in this population.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

Forty DCM patients (55 ± 13 years; 31 male) and 20 healthy adult control subjects (54 ± 13 years; 13 male) free of any cardiovascular diseases were studied. All participants were in sinus rhythm at the time of scan.

CMR acquisition {#Sec4}
---------------

CMR was performed using a 1.5 T system and a 32-channel cardiac phased array receiver coil (Achieva, Philips Healthcare, Best, The Netherlands). Cine CMR, phase contrast images of the ascending aorta, T~1~ mapping and 3 dimensional late gadolinium enhancement (LGE) were obtained in all participants \[[@CR14]\]. T~1~ mapping was performed using a free-breathing slice-interleaved T~1~ (STONE) sequence \[[@CR15]\].

Electrocardiogram monitoring leads were positioned with the subject in the supine position. Vertical and horizontal LV long-axis cine images were acquired using a steady-state free precession (SSFP) sequence. LV volumes and mass were calculated from an LV short-axis stack of cine images extending from the apex to the base (repetition time (TR), 3.3 ms; echo time (TE), 1.6 ms; flip angle (FA), 60°; field-of-view (FOV), 320 × 320 mm; acquisition matrix, 128 × 128; slice thickness, 8 mm; gap, 2 mm) \[[@CR16]\]. Phase contrast images were acquired perpendicular to the proximal ascending aorta to quantify blood flow by following parameters (TR, 15 ms; TE, 6.5 ms; FA, 30°; velocity encoding, 300 cm/s; FOV, 320 × 320 mm; acquisition matrix, 288 × 288; number of phases per cardiac cycle, 36). STONE native T~1~ mapping was acquired in the short axis during free-breaching using slice-tracking with a balanced SSFP readout (5 slices, TR/TE = 2.8/1.4 msec, flip angle = 70, FOV = 360 × 351 mm, voxel size = 2.1 × 2.1 mm, slice thickness = 8 mm, TFE factor = 86, SENSE factor = 2).

Fifteen minutes after the injection of 0.2 mmol/kg gadobenate dimeglumine, LGE images were acquired using a 3 dimensional sequence \[[@CR14]\] with following parameters (TR, 5.3 ms; TE, 2.1 ms; FA, 70°; FOV, 320 × 320 × 125 mm^3^; acquisition matrix, 224 × 224 × 23; spatial resolution,1.4 × 1.4 × 1.5 mm; reconstruction resolution, 0.6 × 0.6 × 0.8 mm).

Image analysis {#Sec5}
--------------

Data were analyzed using a commercial workstation (Extend MR WorkSpace, version 2.3.6.3, Philips Healthcare). To determine LV mass, epi- and endocardial LV borders were manually traced on the short axis images. LV mass was calculated as the sum of the myocardial volume multiplied by the specific gravity (1.05 g/mL) of myocardial tissue \[[@CR17]\]. Left atrial (LA) volume was calculated using biplane area length method \[[@CR18]\]. Papillary muscle morphology (diameter, length and shortening), anterior and posterior mitral leaflet length, mitral annulus diameter (both in 2 chamber and 4 chamber views) and tenting height were measured by cine CMR (Fig. [1](#Fig1){ref-type="fig"}). Papillary muscle shortening was calculated as follows.Fig. 1Measurement of papillary muscle, mitral annulus and tenting height. (**a**) posterior papillary muscle length measurement, (**b**) mitral annulus and tenting height measurement, (**c**) papillary muscle diameter measurement, (**d**) anterior papillary muscle length measurement $$\documentclass[12pt]{minimal}
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Aortic blood flow was determined using the semi-automated algorithms \[[@CR19]\]. Phase offset correction was performed as described previously \[[@CR20]\]. Mitral regurgitation volume was calculated as the difference between the LV stroke volume and ascending aorta forward flow \[[@CR21]\]. Mitral regurgitant fraction was calculated as follows.$$\documentclass[12pt]{minimal}
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For calculating papillary muscle native T~1~ time, both anterior and posterior papillary muscles were manually traced on custom software (MediaCare, Boston, MA, USA) (Fig. [2](#Fig2){ref-type="fig"}). For calculating LV native T~1~ time, the three short axis LV slices were then divided into 6 segments for base and mid slices, 4 segments for apical slice using the anterior right ventricular-LV insertion point as reference. The 16 segment model was used to assess native T~1~ time in each segments. The native T~1~ time from all the segments was averaged to calculate each subjects LV T~1~ time. Motion correction was performed using the adaptive registration of varying contrast-weighted images for improved tissue characterization (ARCTIC) approach \[[@CR22]\]. To evaluate inter-observer variability, measurements of papillary muscle native T~1~ time from 10 DCM patients and 10 healthy adult controls were independently taken by two observers. One of the two observers measured papillary muscle native T~1~ time twice to assess intra-observer variability. The time delay between two read for intra-observer variability was 1 month. Visual assessment was performed to evaluate for LV and papillary muscle scar on LGE.Fig. 2Measurement of native T~1~ time of papillary muscles. Location of anterior and posterior papillary muscle T~1~ measurement. *Blue circle* represents region of interest for T~1~ measurement. *ROI* region of interest

Statistical analysis {#Sec6}
--------------------

Data were analyzed using SPSS software (version 17.0, SPSS, Inc., Chicago, IL, USA) and MedCalc for Windows (version 14.8.1, MedCalc Software, Ostend, Belgium). Continuous values are presented as mean ± standard deviation (SD). Categorical values are expressed as number (%). DCM patients were divided into 2 groups based on the presence or absence of mitral regurgitation. To assess the difference between 3 groups (DCM patients with mitral regurgitation, *n* = 22; DCM patients without mitral regurgitation, *n* = 18; control subjects, *n* = 20), one-way analysis of variance (ANOVA) with Tukey's correction was used for continuous variables. Chi-square test was used to assess the difference for categorical variables. Bland and Altman plot \[[@CR23]\], coefficient of variation (CV) were used to evaluate intra- and inter-observer variability for measuring papillary muscle native T~1~ time. Repeatability coefficients were calculated as 1.96 times the SD of the differences on the Bland-Altman plots. Spearman's correlation coefficient was calculated to evaluate relationship between papillary muscle T~1~ time and papillary muscle morphology (diameter, length and shortening). Multivariate linear regression analysis was performed to identify the determinants of mitral regurgitation severity in DCM patients. Variables with *p*-value \<0.05 in the univariable analysis were included in the multivariable linear regression analysis (stepwise method). *P* value \<0.05 was considered as statistically significant.

Results {#Sec7}
=======

Patients' characteristics {#Sec8}
-------------------------

Table [1](#Tab1){ref-type="table"} summarizes the clinical characteristics of study subjects. There was no significant difference in gender, age, body mass index, systolic and diastolic blood pressure, heart rate between 3 groups. Information of medical therapy was also shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of study subjectsDCM MR (+), *N* = 22DCM MR (-), *N* = 18Controls, *N* = 20*\* P*-value\
DCM MR (+) vs DCM MR (-)*\* P*-value\
DCM MR (+) vs Controls*\* P*-value\
DCM MR (-) vs ControlsDemographics Male, %15 (68 %)16 (89 %)13 (65 %)0.120.830.083 Age, years52 ± 1658 ± 1354 ± 130.320.980.44 Height, cm176 ± 9175 ± 8172 ± 80.990.410.52 Body weight, kg93 ± 2086 ± 1579 ± 150.470.100.67 BMI, kg30 ± 728 ± 627 ± 40.510.210.86 BSA, m^2^2.1 ± 0.32.0 ± 0.21.9 ± 0.20.580.100.57 SBP, mmHg116 ± 14119 ± 17119 ± 120.800.700.99 DBP, mmHg70 ± 1174 ± 1471 ± 100.530.700.59 Heart rate, bpm76 ± 1273 ± 1268 ± 140.770.140.47Medications Aspirin7 (32 %)7 (39 %)-0.64\-- ACE/ARBs18 (82 %)16 (89 %)-0.38\-- Calcium channel blockers2 (9 %)2 (11 %)-0.83\-- Beta blockers17 (77 %)14 (78 %)-0.97\-- Diuretics11 (50 %)7 (39 %)-0.48\-- Aldosterone inhibitors2 (9 %)1 (6 %)-0.67\-- Statin9 (41 %)9 (50 %)-0.57\-- Warfarin5 (8 %)2 (11 %)-0.90\--\**P* value was calculated by one-way ANOVA with Tukey's correction or Chi-square test*ACE* angiotensin converting enzyme inhibitor, *ANOVA* analysis of variance, *ARB* angiotensin receptor blocker, *BMI* body mass index, *BSA* body surface area, *DBP* diastolic blood pressure, *DCM* dilated cardiomyopathy, *HR* heart rate, *MR* mitral regurgitation, *SBP* systolic blood pressure

Cine MRI and LGE findings {#Sec9}
-------------------------

Table [2](#Tab2){ref-type="table"} summarizes CMR findings. LV end-diastolic volume index, LV end-systolic volume index, LV mass index were significantly higher (all *p* \< 0.05) in DCM patients in comparison to controls. Stroke volume index and LV ejection fraction were significantly decreased (*p* \< 0.05) in DCM patients compared to control subjects. LA volume was significantly higher in DCM patients with MR compared to those without MR (*p* = 0.04). LGE of LV myocardium was observed in 8 of 40 (20 %) DCM patients, while no DCM patients had LGE of the papillary muscles. Healthy control subjects did not show any LGE in the LV or the papillary muscles. Table [3](#Tab3){ref-type="table"} shows comparison of papillary muscle parameters. Papillary muscle was significantly thicker, longer in DCM patients in comparison to healthy controls. Regarding mitral annulus diameter, papillary muscle shortening and tenting height, significant difference was also observed between DCM patients with mitral regurgitation and those without mitral regurgitation. Table [4](#Tab4){ref-type="table"} summarizes the intra- and inter-observer variability for measurement of papillary muscle size. Intra class correlation coefficients for papillary muscle size measurement were \>0.80 both for intra- and inter-observer variability.Table 2Comparison of CMR parametersDCM MR (+), *N* = 22DCM MR (-), *N* = 18Controls, *N* = 20*\* P*-value\
DCM MR (+) vs DCM MR (-)*\* P*-value\
DCM MR (+) vs Controls*\* P*-value\
DCM MR (-) vs ControlsCine MRI parameters EDVI, mL/m^2^129 ± 43122 ± 3680 ± 160.79\<0.05\<0.05 ESVI. mL/m^2^89 ± 4384 ± 3632 ± 100.86\<0.05\<0.05 SVI, mL/m^2^40 ± 1138 ± 1048 ± 100.860.040.02 LVEF, %34 ± 1333 ± 1161 ± 40.98\<0.05\<0.05 LVMI, g/m^2^67 ± 2368 ± 1746 ± 90.99\<0.05\<0.05 RVEF, %52 ± 1052 ± 1458 ± 51.000.150.18 LA dimension, mm58 ± 955 ± 752 ± 90.590.060.41 LA area (2 chamber view), cm^2^29 ± 925 ± 6-0.21\-- LA area (4 chamber view), cm^2^28 ± 923 ± 6-0.07\-- LA volume (ml)125 ± 5492 ± 31-0.04 RA dimension, mm51 ± 1052 ± 955 ± 90.980.420.58LGE findings LV LGE3 (15 %)5 (27 %)0 (0 %)0.270.090.01 Papillary muscle LGE0 (0 %)0 (0 %)0 (0 %)\-\--\**P* value was calculated by one-way ANOVA with Tukey's correction or Chi-square test*ANOVA* analysis of variance, *CMR* cardiovascular magnetic resonance, *DBP* diastolic blood pressure, *DCM* dilated cardiomyopathy, *EDV* end-diastolic volume, *EDVI* end-diastolic volume index, *EF* ejection fraction, *ESV* end-systolic volume, *ESVI* end-systolic volume index, *HR* heart rate, *LGE* late gadolinium enhancement, *LV* left ventricle, *LVMI* left ventricular mass index, *MR* mitral regurgitation Table 3Comparison of papillary muscle related parametersDCM MR (+), *N* = 22DCM MR (-), *N* = 18Controls, *N* = 20*\* P*-value\
DCM MR (+) vs DCM MR (-)*\* P*-value\
DCM MR (+) vs Controls*\* P*-value\
DCM MR (-) vs ControlsMaximum anterior PAP diameter, mm11.6 ± 3.310.2 ± 1.57.9 ± 1.30.14\<0.05\<0.05Minimum anterior PAP diameter, mm7.9 ± 1.97.6 ± 1.46.8 ± 0.50.73\<0.050.19Maximum posterior PAP diameter, mm10.6 ± 3.19.3 ± 1.57.0 ± 0.60.14\<0.05\<0.05Minimum posterior PAP diameter, mm6.9 ± 1.77.1 ± 0.95.0 ± 0.50.79\<0.05\<0.05Maximum anterior PAP length, mm44.7 ± 7.642.3 ± 6.334.5 ± 2.80.42\<0.05\<0.05Minimum anterior PAP length, mm37.6 ± 6.831.6 ± 5.423.5 ± 2.9\<0.05\<0.05\<0.05Maximum posterior PAP length, mm40.9 ± 8.437.8 ± 5.832.9 ± 3.10.28\<0.05\<0.05Minimum posterior PAP length, mm33.7 ± 7.327.9 ± 3.522.6 ± 3.1\<0.05\<0.05\<0.05Anterior PAP shortening, %15.8 ± 4.425.5 ± 4.132.0 ± 4.8\<0.05\<0.05\<0.05Posterior PAP shortening, %17.7 ± 5.826.0 ± 3.431.5 ± 4.9\<0.05\<0.05\<0.05Mitral annulus (4chamber), mm37.8 ± 6.632.5 ± 3.828.7 ± 1.1\<0.05\<0.05\<0.05Mitral annulus (2chamber), mm38.5 ± 4.534.2 ± 5.131.6 ± 2.0\<0.05\<0.05\<0.05Tenting height, mm10.3 ± 1.16.1 ± 1.72.7 ± 1.3\<0.05\<0.05\<0.05Anterior mitral leaflet length, mm23.6 ± 3.519.9 ± 2.321.7 ± 1.6\<0.050.060.11Posterior mitral leaflet length, mm13.9 ± 4.012.6 ± 1.910.4 ± 1.40.27\<0.05\<0.05\**P* value was calculated by one-way ANOVA with Tukey's correction*ANOVA* analysis of variance, *DCM* dilated cardiomyopathy, *MR* mitral regurgitation, *PAP* papillary muscle Table 4Intra- and inter-observer variability for measurement of papillary muscle sizeIntra observer variabilityInter observer variabilityICC95 % CIICC95 % CIMaximum papillary muscle diameter0.930.84--0.970.920.81--0.97Minimum papillary muscle diameter0.870.69--0.940.820.61--0.93Maximum papillary muscle length0.910.78--0.960.880.73--0.95Minimum papillary muscle length0.910.78--0.960.860.70--0.95*CI* confidence interval, *ICC* intra class correlation coefficients

Comparison of papillary muscle T~1~ time between cardiomyopathy and healthy control subjects {#Sec10}
--------------------------------------------------------------------------------------------

Figure [3](#Fig3){ref-type="fig"} illustrates individual papillary muscle and LV T~1~ time for 3 groups. Mean anterior papillary muscle T~1~ time was 1127 ± 36 msec for DCM with mitral regurgitation (*p* \< 0.05 vs DCM without mitral regurgitation; *p* \< 0.05 vs healthy controls), 1063 ± 16 msec for DCM without mitral regurgitation (*p* = 0.29 vs healthy controls) and 1051 ± 20 msec for healthy controls. Mean posterior papillary muscle T~1~ time was 1124 ± 30 msec for DCM with mitral regurgitation (*p* \< 0.05 vs DCM without mitral regurgitation; *p* \< 0.05 vs healthy controls), 1062 ± 19 msec for DCM without mitral regurgitation (*p* = 0.51 vs healthy controls) and 1053 ± 25 msec for healthy controls. LV native T~1~ time was significantly elevated in DCM patients in comparison to healthy controls (*p* \< 0.05, Fig. [3](#Fig3){ref-type="fig"}), but similar between DCM patients with mitral regurgitation and those without mitral regurgitation (1129 ± 38 msec vs 1134 ± 58 msec, *p* = 0.93). Figure [4](#Fig4){ref-type="fig"} demonstrates regional LV native T~1~ time in each segments. There was no substantial variability across 16 segments both in DCM patients and controls. In addition, there was no significant correlation between papillary muscle T~1~ time and mid-level LV T~1~ time (*r* = 0.31, *p* = 0.05 by Spearman's correlation coefficient). There was no significant difference in T~1~ time between base, mid and apical slices (base, 1125 ± 52 msec; mid, 1130 ± 47 msec; apex, 1138 ± 54 msec, *p* = 0.53 by one-way ANOVA). Figure [5](#Fig5){ref-type="fig"} shows the relationship between papillary muscle T~1~ time and papillary muscle morphology. Elevated papillary muscle T~1~ time was associated with increased papillary muscle diameter, increased papillary muscle length and decreased papillary muscle shortening.Fig. 3Comparison of papillary muscle native T~1~ time and left ventricular T~1~ time. Papillary muscle T~1~ time was significantly elevated in DCM patients with mitral regurgitation in comparison to DCM patients without mitral regurgitation and healthy controls. *DCM* dilated cardiomyopathy, *MR* mitral regurgitation Fig. 4Regional left ventricular native T~1~ time in each segments. There was no substantial variability across 16 segments both in DCM patients and controls. *DCM* dilated cardiomyopathy, *MR* mitral regurgitation Fig. 5Relationship between papillary muscle native T~1~ time and morphology. Papillary muscle native T~1~ time was correlated with papillary muscle diameter, length and shortening

Relationship between papillary muscle T~1~ time and mitral regurgitant fraction {#Sec11}
-------------------------------------------------------------------------------

Figure [6](#Fig6){ref-type="fig"} shows the relationship between papillary muscle T~1~ time and mitral regurgitant fraction in DCM patients. Mitral regurgitant fraction was significantly correlated with both anterior and posterior papillary muscle T~1~ time (*p* \< 0.05) but not with LV myocardial T~1~ time (*p* = 0.67). Table [5](#Tab5){ref-type="table"} summarizes the results of multivariate linear regression analysis for determinants of mitral regurgitant fraction in all DCM patients (*n* = 40). In the multivariate analysis, average of anterior and posterior papillary muscle native T~1~ time was employed for analysis. Multivariate linear regression analysis identified papillary muscle native T~1~ time (β = 0.10, 95 % CI: 0.03--0.17, *p* \< 0.05) as an independent determinant of mitral regurgitant fraction. Table [6](#Tab6){ref-type="table"} shows the results of multivariate linear regression analysis for determinants of mitral regurgitant fraction in DCM patients with MR (*n* = 22). Multivariable linear regression analysis identified posterior papillary muscle maximum diameter (β = 1.32, 95 % CI: 0.50--2.16, *p* \< 0.05) and papillary muscle native T~1~ time (β = 0.11, 95 % CI: 0.03--0.20, *p* \< 0.05) as independent determinants of mitral regurgitant fraction.Fig. 6Relationship between papillary muscle native T~1~ time and mitral regurgitant fraction. Papillary muscle native T~1~ time was associated with mitral regurgitant fraction in DCM patients. *DCM* dilated cardiomyopathy Table 5Univariate and multivariate linear regression analysis for determinants of mitral regurgitant fraction in all DCM patients (*n* = 40)Univariable analysisMultivariable analysisB95 % CI for β*P*-valueB95 % CI for β*P*-valueAge, year−0.01−0.20--0.180.90\-\--Gender, male−3.99−10.50--2.530.22\-\--Body mass index, kg/m^2^0.22−0.21--0.710.28\-\--LVEDVI, mL/m^2^0.05−0.02--0.120.18\-\--LVEF, %−0.16−0.40--0.070.17\-\--LVMI, g/m^2^0.06−0.08--0.200.37\-\--Left atrial area (4 chamber), cm^2^0.560.23--0.91\<0.050.17−1.05--1.390.25Left atrial area (2 chamber), cm^2^0.36−0.16--0.890.17\-\--Left atrial volume, cm^3^0.100.04--0.16\<0.05−0.01−0.21--0.200.95Mitral annulus (4 chamber), mm0.43−0.01--0.870.06\-\--Tenting height, mm2.281.38--3.17\<0.050.61−0.37--1.590.21Anterior papillary muscle maximum diameter, mm1.280.34--2.23\<0.050.29−0.59--1.160.51Posterior papillary muscle maximum diameter, mm1.370.35--2.38\<0.050.73−0.23--1.680.13Anterior papillary muscle shortening, %−0.87−1.20-- −0.54\<0.05−0.10−0.68--0.490.74Posterior papillary muscle shortening, %−0.92−1.24-- −0.60\<0.05−0.21−0.75--0.320.42Papillary muscle T~1~ time, sec0.160.12--0.21\<0.050.100.03--0.17\<0.05Variables with *p* value \< 0.05 in univariate analysis were included in multivariable analysis*CI* confidence interval, *DCM* dilated cardiomyopathy, *LVEDVI* left ventricular end-diastolic volume index, *LVEF* left ventricular ejection fraction, *LVMI* left ventricular mass index, *MR* mitral regurgitation Table 6Univariate and multivariate linear regression analysis for determinants of mitral regurgitant fraction in DCM patients with MR (*n* = 22)Univariable analysisMultivariable analysisB95 % CI for β*P*-valueB95 % CI for β*P*-valueAge, year0.08−0.11--0.260.41\-\--Gender, male−0.49−6.85--5.860.87\-\--Body mass index, kg/m^2^0.17−0.29--0.640.44\-\--LVEDVI, mL/m^2^0.05−0.02--0.110.17\-\--LVEF, %−0.17−0.40--0.050.12\-\--LVMI, g/m^2^0.06−0.06--0.200.28\-\--Left atrial area (4 chamber), cm^2^0.340.01--0.68\<0.050.13−0.24--0.300.85Left atrial area (2 chamber), cm^2^0.14−0.21--0.490.42\-\--Left atrial volume, cm^3^0.05−0.01--0.110.08Mitral annulus (4 chamber), mm−0.05−0.50--0.410.83\-\--Tenting height, mm1.46−1.09--4.010.24\-\--Anterior papillary muscle maximum diameter, mm0.64−0.22--1.510.14\-\--Posterior papillary muscle maximum diameter, mm0.930.05--1.82\<0.051.320.50--2.16\<0.05Anterior papillary muscle shortening, %0.31−1.12-- −0.210.17\-\--Posterior papillary muscle shortening, %−0.51−0.97-- −0.05\<0.05−0.17−0.58--0.230.41Papillary muscle T~1~ time, sec0.110.02--0.20\<0.050.110.03--0.20\<0.05Variables with *p* value \< 0.05 in univariate analysis were included in multivariable analysis*CI* confidence interval, *DCM* dilated cardiomyopathy, *LVEDVI* left ventricular end-diastolic volume index, *LVEF* left ventricular ejection fraction, *LVMI* left ventricular mass index, *MR* mitral regurgitation

Variability of papillary muscle T~1~ measurement {#Sec12}
------------------------------------------------

Repeatability coefficients of anterior papillary muscle T~1~ time were 2.0 % for intra-observer variability, 4.1 % for inter-observer variability. Repeatability coefficients of posterior papillary muscle native T~1~ time were 1.3 % for intra-observer variability, 5.0 % for inter-observer variability. Variability of papillary muscle native T~1~ time measurement was high (CV of intra-observer variability: 0.9 % for anterior papillary muscle and 0.7 % for posterior papillary muscle; CV of inter-observer variability: 1.6 % for anterior papillary muscle and 1.8 % for posterior papillary muscle).

Discussion {#Sec13}
==========

To the best of our knowledge, this study is the first investigation to examine the feasibility and variability of papillary muscle native T~1~ time measurement, and to investigate the relationship between papillary muscle T~1~ time and severity of functional mitral regurgitation in DCM patients. We found a significant difference of papillary muscle native T~1~ time between DCM patients with mitral regurgitation and those without mitral regurgitation, a correlation between papillary muscle native T~1~ time and mitral regurgitant fraction in DCM patients and low variability of papillary muscle T~1~ time measurement.

Papillary muscle T~1~ time and papillary muscle morphology in DCM patients {#Sec14}
--------------------------------------------------------------------------

Previous echocardiographic studies have shown that the papillary muscle dysfunction is observed in several cardiovascular diseases. Papillary muscle shortening has been assessed using transthoracic echocardiography and used as a functional parameter \[[@CR24], [@CR25]\]. In myocardial infarction patients, papillary muscle function was substantially reduced compared to healthy controls (papillary muscle shortening: 15 ± 14 % vs 30 ± 8 %) \[[@CR25]\]. Reduced papillary muscle shortening has also been reported in cardiomyopathy patients including hypertrophic cardiomyopathy or DCM \[[@CR24], [@CR26]\]. In the current study, we measured papillary muscle diameter, length and shortening using cine CMR and showed that papillary muscle shortening was significantly reduced in DCM patients in comparison to healthy controls. This absolute value and difference findings were consistent with previous echocardiographic studies. In addition, we found a significant difference in papillary muscle shortening between DCM patients with mitral regurgitation in comparison to those without mitral regurgitation, suggesting that papillary muscle dysfunction may be contributing to mitral regurgitation.

The maximum papillary muscle diameter was approximately 7 mm in healthy controls and 10 mm in DCM patients. Elevated papillary muscle native T~1~ time was associated with larger diameter, longer length, decreased shortening in DCM patients. This finding suggested that papillary muscle T~1~ time might reflect papillary muscle pathological changes in DCM patients (i.e. papillary muscle fibrosis). Furthermore, papillary muscle native T~1~ time was increased in DCM patients with mitral regurgitation compared to those without mitral regurgitation, but LV native T~1~ time was similar between 2 groups. These results suggest that the papillary muscle native T~1~ time may be a more sensitive for the mechanical stress induced by functional mitral regurgitation. A previous study by Okayama et al. showed that LGE evidence of bilateral papillary muscle infarction correlated with LV remodeling and functional mitral regurgitation \[[@CR27]\]. Although the assessment of papillary muscle abnormality is feasible by LGE, an important advantage of non-contrast native T~1~ mapping is the ability to evaluate papillary muscle abnormality in patients with renal dysfunction who are at high risk of systemic nephrogenic fibrosis \[[@CR28]\]. In addition, we did not observe any papillary muscle LGE in this study, suggesting that the papillary muscle pathological change is *diffuse* rather than *focal* in DCM patients.

Clinical implication {#Sec15}
--------------------

We found significant difference in papillary muscle native T~1~ time between DCM patients with mitral regurgitation and those without mitral regurgitation. However, no significant difference was found in LV native T~1~ time. In addition, papillary muscle T~1~ time was independently correlated with severity of functional mitral regurgitation after adjustment of conventional determinants, including tenting height, mitral annulus diameter. Previous transthoracic echocardiographic studies showed that tenting height is a strong indicator of effective orifice area in patents with LV dysfunction and functional mitral regurgitation \[[@CR29]\]. Further study is necessary to elucidate if papillary muscle native T~1~ time has prognostic value in DCM patients.

Study limitations {#Sec16}
-----------------

Our study has several limitations. The sample size was modest and the study population was limited to DCM patients and healthy controls. Our T~1~ mapping sequence, STONE, has not been histologically validated for papillary muscle T~1~ mapping. Therefore, we do not know the true cause of the elevated papillary muscle native T~1~ time in DCM patients. Although T~1~ mapping images acquired by STONE were motion corrected, relatively low spatial resolution of T~1~ mapping images and the partial volume effect are not negligible for T~1~ measurement of papillary muscle. To avoid partial volume effect with blood pool, we've carefully placed the ROI on papillary muscle much smaller than actual papillary muscle diameter not to include the pixels from LV blood pool. As shown on Fig. [2](#Fig2){ref-type="fig"}, size of ROI on papillary muscle was much smaller than actual size of papillary muscle. The pixel size of ROI drawn on papillary muscle was 16--40 pixels. It would be also interesting to investigate the relationship between papillary muscle extra cellular volume (ECV) and mitral regurgitant fraction. However, calculation of ECV requires registration between native and post-contrast T1 images, which will be challenging for a mobile and small papillary muscle anatomy. Regarding LV ECV, in our cohort, there were 21 DCM patients and 9 controls with ECV data. Significant difference was found between DCM patients and controls in LV ECV averaged over 16 segments (0.30 ± 0.04 vs 0.27 ± 0.02, *p* = 0.03). However, no significant difference was found between DCM patients with MR and those without MR (0.31 ± 0.05 vs 0.29 ± 0.04, *p* = 0.63). A larger, more diverse study is required to assess the clinical relevance of papillary muscle native T~1~ time. Because this study is a cross-sectional study, we can't say any causal relationship between papillary muscle T~1~ time and functional mitral regurgitation. Examination of the potential difference of the time course of T~1~ change in the myocardium and papillary muscle would also be of interest, but is beyond the scope of this study.

Conclusions {#Sec17}
===========

Measurement of papillary muscle native T~1~ time is both feasible and reproducible. This CMR approach successfully detects abnormal papillary muscle native T~1~ time in DCM patients with functional mitral regurgitation.
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